CompletedPhase 2

Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)

40 participantsStarted 2013-10

Plain-language summary

The purpose of this study is to evaluate pregnancy, delivery, and neonatal outcomes in subjects who maintain ongoing clinical pregnancies through Week 10 of gestation in NT-03.

Who can participate

Age range21 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least one dose of study drug administered in NT-03 * Ongoing clinical pregnancy at Week 10 of gestation * Able and willing to enroll in NT-04 Exclusion Criteria: • None

What they're measuring

Number of live births

Timeframe: Within approximately 7 months after NT-03

Trial details

NCT IDNCT01978561

SponsorNora Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08

View on ClinicalTrials.gov More Repeated IVF Failure trials